YEAR IN REVIEW
INFECTIOUS DISEASES AND IMMUNITY IN GLOBAL HEALTH (IDIGH) PROGRAM
First large-scale efficacy studies of a plant-derived influenza vaccine
Dr. Brian Ward and colleagues showed in two multicentre phase 3 efficacy studies that a recombinant quadrivalent virus-like particle (QVLP) influenza vaccine, manufactured in plants by Medicago, is safe and protective against influenza. QVLP vaccines might address some of the limitations of current vaccines. Published in The Lancet.
Repurposing facilities to advance COVID-19 research
WIth a seed grant from the MUHC Foundation and partners, Dr. Marcel Behr and his team repurposed existing Containment Level 3 facilities at the RI-MUHC and McGill University to conduct live SARS-Cov-2 research. This research has accelerated with funding from the Canada Foundation for Innovation.
Study of hydroxychloroquine usage may help personalize lupus treatment
Dr. Sasha Bernatsky and postdoctoral fellow Celline Brasil, PhD, identified predictors of unsuccessful hydroxychloroquine tapering and discontinuation in lupus patients. This understanding of outcomes is a first step toward personalized treatment. Published in Journal of Arthritis Care and Research.
Selected news links
- First human efficacy study of a plant-derived influenza vaccine - The Lancet
- New study of hydroxychloroquine usage may help personalize lupus treatment
- Paving the way for COVID-19 research
- $2M funding to mitigate COVID-19 impact on tuberculosis services
- Spike in peanut and nut anaphylaxis in children at Halloween and Easter
- Zombie cells and flu fighters
- More IDIGH Program news